This platform leverages a multimodal mechanism of action: killing tumor cells via CAR and NKRs (e.g., NKG2D and DNAM-1), modulating the immunosuppressive TME via NKT TCR-mediated recognition of CD1d+ TAMs and MDSCs, and targeting CD70+ alloreactive T cells via CAR, thereby reducing allorejection (Figure 1P). This evidence concerns the gene CD226 and neoplasm.